Share

    


Home / Search Results

Search Results

You searched for:

ACCCBuzz spoke with Luis E. Raez, MD, FACP, FCCP, to learn more about the importance of closing the gap in access to biomarker testing and strategies to improve equity and inclusion in precision medicine.
With the variety of models and titles that have emerged under precision medicine stewardship, learn how one cancer program is breaking down the this complex landscape into streamlined workflows to improve efficiency and better support growing test volumes.
ACCC shares how a precision medicine steward—a dedicated navigator focused specifically on biopsy samples and biomarker testing processes and results—can make a daunting biomarker testing process incredibly efficient for cancer programs and practices everywhere.
Introduced in 2021, the Cancer Patient Equity Act seeks to provide coverage of certain cancer diagnostic and laboratory tests under Medicare, Medicaid, and the Children's Health Insurance Program, and more.
Care optimization is everything in today’s rapidly changing healthcare landscape. Learn how ACCC's nationwide quality improvement (QI) initiative helped Southern Ohio Medical Center Cancer Center develop and implement plans to support the optimization of care for patients diagnosed with Stages III and IV non-small cell lung cancer (NSCLC).
Communities around the globe recognize August 1 as World Lung Cancer Day—a day to commemorate, educate, and support individuals and families impacted by lung cancer. Read highlights on a few ACCC initiatives that are helping cancer care teams better support their patients with this disease.
To fill a care gap, The James Cancer Hospital opened a new set of front doors to its facility—The James Cancer Diagnostic Center—to ensure all patients with a concern for cancer could be quickly evaluated, even if they didn’t have a confirmed diagnosis.
Measurable residual disease (MRD) has gained traction as a compelling marker for disease status across various hematologic malignancies, including multiple myeloma. Learn how MRD is uniquely suited to help evaluate the depth of treatment response.
With data already demonstrating the role of MRD for CLL response assessment and prognosis, cancer programs should prepare themselves for implementation of MRD testing for appropriate patients.
As precision medicine becomes more common in the management of lung cancer, little is understood about the patient experience with biomarker testing, particularly of underserved patients. This study used survey and focus group methodology to determine patient perspectives on the educational needs within this community.
This ACCC education program shares key highlights from a national survey of thoracic surgeons, radiation oncologists, and medical oncologists on the barriers that exist in the ideal management of patients with NSCLC.
St. Vincent Hospital implemented a collaborative method of care that uses genetic counselor extenders to increase patient access to risk assessment and genetic testing.